Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004233 · ClinicalTrials.gov registry record · Phase 2
S9915 Triacetyluridine, Fluorouracil, and Leucovorin in Treating Patients With Unresectable, Locally Advanced, or Metastatic Cancer of the Esophagus or Stomach
A Phase 2 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
NCT00004233 is a Phase 2 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 65 participants.
The verdict
NCT00004233, a Phase 2 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as triacetyluridine may protect normal cells from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of triacetyluridine, fluorouracil, and leucovorin in treating patients who have unresectable, locally advanced, or metastatic cancer of the esophagus or stomach.
Interventions
- DRUG fluorouracil
- DRUG leucovorin calcium
- DRUG triacetyluridine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2001-02 |
| Est. Completion | 2007-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004233
The ClinicalTrials.gov registry entry for NCT00004233 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which fluorouracil is the first listed.
NCT00004233 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004233 about?
NCT00004233 is a clinical study titled "S9915 Triacetyluridine, Fluorouracil, and Leucovorin in Treating Patients With Unresectable, Locally Advanced, or Metastatic Cancer of the Esophagus or Stomach". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as triacetyluridine may protect normal cells from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of triacetyluridi...
What is the current status of trial NCT00004233?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2001-02. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00004233?
The interventions under investigation include: fluorouracil (DRUG), leucovorin calcium (DRUG), triacetyluridine (DRUG).
Who is sponsoring clinical trial NCT00004233?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.